Pharma: Boehringer-Chef über Potenziale der Pharmabranche: Westen hat „kein Monopol auf Innovation“
Chinesische Unternehmen holen bei der Entwicklung neuer Medikamente rasant auf. Shashank Deshpande, Vorstandschef von Boehringer Ingelheim, sieht darin auch einen Ansporn für Europa.
Seoul - Boehringer Ingelheim's CEO Shashank Deshpande views the growing competition from China as a stimulus for the pharmaceutical industry. "Competition invigorates the business. Europe and America do not have a monopoly on innovation," Deshpande told Deutsche Presse-Agentur at the sidelines of the Asia-Pacific Conference of German Industry in Seoul.
He emphasized the increasing importance of Asia-Pacific region for innovations in the pharmaceutical industry during the economic conference in the South Korean capital. Boehringer Ingelheim is conducting more than 200 clinical studies in the region, excluding China, and collaborates with approximately 160 scientific institutions.
In South Korea alone, the company currently runs around 50 clinical studies. Deshpande also believes that artificial intelligence could fundamentally change pharmaceutical research. At the end of October, Boehringer Ingelheim announced a strategic partnership with US technology giant Microsoft to explore AI-assisted clinical trials, potentially accelerating the development of a new medicine by up to 50 percent.
Chancellor Friedrich Merz opened the Asia-Pacific Conference on Friday, advocating once again for a global network for free trade based on international rules. Around 1000 business representatives from Germany and the Indo-Pacific region attended the Asia-Pacific Conference.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
